Clinical Trial Update: Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis [Phase 1]

View source ↗

Summary

A Phase 1 study of VG2025 delivered intraperitoneally in patients with advanced solid tumors and peritoneal carcinomatosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peritoneal Carcinomatosis

Drugs mentioned

• VG2025

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Solid Tumor, Carcinomatosis | Phase 1 | Status: WITHDRAWN